Chemotherapy in the treatment and control of leishmaniasis.
Drugs remain the most important tool for the treatment and control of both visceral and cutaneous leishmaniasis. Although there have been several advances in the past decade, with the introduction of new therapies by liposomal amphotericin, oral miltefosine and paromomycin (PM), these are not ideal drugs, and improved shorter duration, less toxic and cheaper therapies are required. Treatments for complex forms of leishmaniasis and HIV co-infections are inadequate. In addition, full deployment of drugs in treatment and control requires defined strategies, which can also prevent or delay the development of drug resistance.
Alvar
Jorge
J
Department for Control of Neglected Tropical Diseases, World Health Organization, 20 Avenue Appia CH-1211 Geneva 27, Switzerland.
Croft
Simon
S
Olliaro
Piero
P
D000818:Animals; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy / Q000469:parasitology; D004285:Dogs; D004351:Drug Resistance; D005260:Female; D015658:HIV Infections / Q000150:complications; D006291:Health Policy; D006801:Humans; D007896:Leishmaniasis / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology* / Q000517:prevention & control; D011247:Pregnancy; D015597:Pregnancy Complications, Parasitic / Q000188:drug therapy
D000981:Antiprotozoal Agents